At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
The company is doubling its chemistry research capacity that should commission by Q2'FY22
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
Subscribe To Our Newsletter & Stay Updated
